BTK and hemophagocytic syndrome: Activated T cells and macrophages mutually stimulate each other, forming a positive feedback loop that ultimately leads to uncontrolled, “storm-level” release of cytokines, thereby inducing hemophagocytic syndrome.[13] Second-generation BTK inhibitors such as zanubrutinib and acalabrutinib can reduce off-target effects by improving target selectivity.